Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



Tykerb

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}}Date: {{TODAY}} Patient's ID: {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} Physician's Name: {{PHYFIRST}} {{PHYLAST}} Specialty:			
1.	What is the patient's diagnosis? Central nervous system (CNS) metastases from breast cancer Breast cancer Chordoma Colorectal cancer Other		
2.	What is the ICD-10 code?		
3.	Is this a request for continuation of therapy with Tykerb? \square Yes \square No If No, skip to #5.		
4.	Has the patient experienced disease progression or an unacceptable toxicity with Tykerb? ☐ Yes ☐ No <i>No further questions</i> .		
5.	Will Tykerb be given in any of the following regimens? ☐ Single agent ☐ In combination with capecitabine ☐ In combination with trastuzumab ☐ In combination with an aromatase inhibitor (e.g., letrozole, anastrazole, or exemestane) ☐ In combination with an aromatase inhibitor (e.g., letrozole, anastrazole, or exemestane) with trastuzumab ☐ Other		
6.	Does the patient have recurrent, advanced, or metastatic disease? ☐ Recurrent disease ☐ Advanced disease ☐ Metastatic disease ☐ None of the above		
Complete the following section based on the patient's diagnosis, if applicable.			
<u>Sec</u> 7.	what is the patient's human epidermal growth factor receptor 2 (HER2) status? ACTION REQUIRED: Attach human epidermal growth factor receptor 2 (HER2) testing results. HER2-positive HER2-negative Unknown		

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tykerb SGM - 6/2020.

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}		
8. If the diagnosis is breast cancer, does the patient have hormone receptor-positive disease? **ACTION REQUIRED: If Yes, attach hormone receptor testing results.		
Section B: Chordoma 9. What is the patient's epidermal growth factor receptor (EGF growth factor receptor (EGFR) testing results. □ EGFR-positive □ EGFR-negative □ Unknown	FR) status? ACTION REQUIRED: Attach epidermal	
Section C: Colorectal Cancer 10. What is the patient's human epidermal growth factor recept human epidermal growth factor receptor 2 (HER2) testing HER2-amplified Unknown Other	results.	
11. Does the patient have RAS wild-type disease? ☐ Yes ☐	No	
12. Is the patient appropriate for intensive therapy? □ Yes □ No If No, no further questions		
13. Will Tykerb be used as subsequent therapy for progression of	or advanced or metastatic disease? Yes No	
I attest that this information is accurate and true, and the information is available for review if requested by CVS C	aremark or the benefit plan sponsor.	
Prescriber or Authorized Signature	Date (mm/dd/yy)	

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tykerb SGM - 6/2020.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081